Once a medical devices firm, Sharps Technology is betting big on Solana.Once a medical devices firm, Sharps Technology is betting big on Solana.

Sharps Technology raises $400M+ to launch Solana treasury

Sharps Technology, once a medical device and pharmaceutical firm, pivots to become a Solana treasury firm.

Summary
  • Sharps Technology announced a PIPE deal to buy $400M in Solana
  • A list of major institutions is backing the Sharps Technology deal
  • Firm lauds Solana’s staking yields and strong DeFi ecosystem

Solana (SOL) continues to get attention among traditional investors. On Monday, August 25, Sharps Technology, a publicly traded company on the Nasdaq, announced it is raising $400 million in a private placement.

The deal will follow the pattern of a private placement in public equity, as Sharps Technology stock is publicly traded. Namely, the company is raising capital by selling shares to a group of institutional backers, including Pantera Capital, ParaFi, FalconX, and Phoenix Capital.

Sharps Technology pivots from medical devices to Solana

The Company’s newly appointed Chief Investment Officer and Board member, Alice Zhang, stated that the decision to back Solana comes from the network’s performance. Namely, Solana offers low-cost settlements for a broad range of use cases, which is attractive to institutions.

Sharps Technology, a medical device and pharmaceutical packaging firm, is just one of the companies that is pivoting to become a treasury firm. On the same day of its pivot, Galaxy, Jump, and Multicoin have teamed up to buy $1 billion of Solana tokens.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.